EG 427 (private company)

EG 427 is a French biotechnology company doing pinpoint gene therapy, exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1), notably its ability to establish lifelong latency in peripheral neurons, in order to ensure highly specific and durable expression of the transgene to treat, in the long run, patients with severe, chronic and localized diseases, starting with peripheral nervous system disorders.